Nalanda India Equity Fund Limited increased its stake in Jyothy Laboratories to 7.60% following an open market acquisition. The fund purchased 3,102,384 shares on September 2, 2026, raising its total holding from 6.76%.

The transaction was executed via the exchange, with settlement completed on September 3, 2026. The disclosure was filed with the Bombay Stock Exchange on September 10, 2026.

Acquisition Details

The acquirer is not part of the promoter group. The purchase was made through open market transactions rather than off-market deals or preferential allotments.

Regulatory Context

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Jyothy Laboratories Limited has a total equity share capital of 367,214,511 shares. This figure remained unchanged after the acquisition, indicating no new issuance of shares occurred during this period.

No encumbrances, pledges, or voting rights other than those attached to equity shares were reported for the acquired stake. The total diluted share capital also stands at 367,214,511 shares.

Jyothy Laboratories will hold a one-on-one investor meeting with Canara Robeco Mutual Fund on September 17, 2026. The company disclosed the engagement under SEBI Listing Regulations.

The meeting is scheduled as part of routine investor relations activities. Representatives of the company will attend the session. The schedule may change due to exigencies on the part of the investor or the company.

Regulatory Disclosure

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jyothy Labs Limited confirmed that no Unpublished Price Sensitive Information (UPSI) is proposed to be shared during the meeting.

Shreyas Trivedi, Head – Legal & Company Secretary, signed the intimation. The latest investor presentation remains available on the company website.